Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease

Evidence for efficacy is based on the results from the GVHD-1 and GVHD-2 studies
01 Feb 2022
Haematologic malignancies

On 15 December 2021, the US Food and Drug Administration (FDA) approved abatacept (Orencia, Bristol-Myers Squibb Company) for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and paediatric patients 2 years of age and older undergoing haematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. This is the first drug approved to prevent aGVHD.

The application included use of real world data in the determination of clinical effectiveness. Real world data is clinical data routinely collected from a variety of sources, including registry data, to generate real world evidence.  

Efficacy was evaluated in two studies in patients 6 years and older undergoing HSCT from a matched or 1 allele-mismatched unrelated donor.  

GVHD-1 (NCT 01743131) was a randomised (1:1), double-blind, placebo-controlled clinical study of patients who underwent an 8 of 8 Human Leukocyte Antigen (HLA)-matched HSCT and received abatacept or placebo in combination with a CNI and MTX. While severe (grade III-IV) aGVHD-free-survival assessed at day 180 after transplantation was not significantly improved in patients who received Orencia compared to patients who received a placebo (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.26, 1.18), the overall survival (OS) rate at day 180 after HSCT was 97% (95% CI 89%, 99%) for patients who received abatacept compared to 84% (95% CI 73%, 91%) for patients who received a placebo (HR 0.33, 95% CI 0.12, 0.93). The moderate-severe (grade II-IV) aGVHD-free survival rate at day 180 after HSCT was 50% (95% CI 38%, 61%) for patients who received abatacept compared to 32% (95% CI 21%, 43%) for patients who received a placebo (HR 0.54, 95% CI 0.35, 0.83).

Additional evidence of effectiveness was provided by GVHD-2, a clinical study using data from the Center for International Blood and Marrow Transplant Research (CIBMTR) in patients who underwent a 7 of 8 HLA-matched HSCT between 2011 and 2018. This registry-based study analyzed outcomes of 54 patients treated with abatacept for the prophylaxis of aGVHD, in combination with a CNI and MTX, versus 162 patients randomly selected from the CIBMTR registry treated with a CNI and MTX alone. The OS rate at day 180 after HSCT was 98% (95% CI 78%, 100%) for patients who received abatacept in combination with CNI and MTX compared to 75% (95% CI 67%, 82%) for patients who received CNI and MTX alone.

The most common adverse reactions (≥10%) of abatacept for the prophylaxis of aGVHD are anaemia, hypertension, CMV reactivation/CMV infection, pyrexia, pneumonia, epistaxis, CD4 lymphocytes decreased, hypermagnesemia and acute kidney injury. Patients who receive abatacept should receive antiviral prophylaxis for Epstein-Barr virus infection before starting treatment and for 6 months post-transplantation and be monitored for cytomegalovirus infection/reactivation for 6 months post-transplant. 

The recommended abatacept dose depends upon the age of the patient and is described in prescribing information. Full prescribing information for Orencia is available here.

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with Health Canada, Switzerland’s Swissmedic, and Israel’s Ministry of Health. The application reviews are ongoing at the other regulatory agencies 

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review, breakthrough designation and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.